515 results on '"Sui Weiwei"'
Search Results
2. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma
3. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)
4. Highly sensitive and low-temperature triethylamine sensor based on in situ growth of hierarchical α-MoO3 flowers
5. BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review
6. In-situ grown α-MoO3 hollow microspheres achieve high-sensitivity detection of trimethylamine
7. Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: a case report and literature review
8. Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
9. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
10. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
11. Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
12. A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma
13. Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant
14. γδ and αβ T‐cell large granular lymphocytic leukaemia have similar characteristics and outcomes.
15. Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
16. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
17. Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia
18. Mussel-inspired pH-responsive copper foam with switchable wettability for bidirectional oil-water separation
19. Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
20. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
21. Subtype Distribution, Clinical Features, and Survival in B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases
22. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
23. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
24. Supplementary Figure S2 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
25. Supplementary Methods S1 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
26. Supplementary Table S3 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
27. Data from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
28. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy
29. The impact of response kinetics for multiple myeloma in the era of novel agents
30. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
31. MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities
32. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
33. Gemcitabine‐based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes
34. Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma
35. The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma
36. Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features
37. Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
38. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
39. Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma
40. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma
41. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
42. FIGURE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
43. TABLE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
44. Table S2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
45. TABLE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
46. Figure S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
47. FIGURE 4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
48. FIGURE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
49. FIGURE 3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
50. Data from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.